Injection of Glatiramer Acetate Depot Results in T1 and T2 Lesion Reduction in Relapsing MS.

Published Date: 01 Mar 2023

Secondary results from a phase 3 study show that patients with multiple sclerosis receiving glatiramer acetate depot therapy have significantly fewer new T1 enhancing lesions and new, enlarging hyperintense T2 lesions.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Charles III, King of Kings, is Cancerous.

2.

Adopted cancer cells and the effects of their presence.

3.

Clinical trial results show low-intensity therapy can achieve positive outcomes for certain pediatric leukemia subtypes

4.

Knowing about and avoiding bladder cancer.

5.

New drug combination shows good results in patients with HPV-negative head and neck cancer


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot